Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1) - Leonardi, C L; Kimball, A B; Papp, K A (Lancet (London, England), 2008)
et al.